All-Cause and Cause-Specific 30-Day Readmissions After Left Ventricular Assist Device Implantation: Comparing the HeartMate 3 Versus Pre-HeartMate 3 Eras.

Competing Interests: Declaration of Competing Interest Dr. Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American Heart Association (number 929502), National Heart Lung and Blood Institute, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim/ Lilly, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, Sanofi, and scPharmaceuticals; serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Corteria Pharmaceuticals, CSL Vifor, Merck, PharmaIN, Roche Diagnostics, Sanofi, Tricog Health, and Urovant Pharmaceuticals; and has received speaker fees from Boehringer Ingelheim, cytokinetics, and Roche Diagnostics. The remaining authors have no competing interests to declare.